Trials / Completed
CompletedNCT01242215
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients
A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination With Sulfonylurea in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 243 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and sulfonylurea in patients with diabetes mellitus.
Detailed description
This study is to evaluate the efficacy and safety of ASP1941 in combination with sulfonylurea in subjects with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control with sulfonylurea alone. The effects of ASP1941 are compared with those of placebo. Double blind period continues for 24 weeks followed by open period in each patient.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | ipragliflozin | oral |
| DRUG | Placebo | oral |
| DRUG | Sulfonylurea | oral |
Timeline
- Start date
- 2010-09-17
- Primary completion
- 2012-04-25
- Completion
- 2012-04-25
- First posted
- 2010-11-16
- Last updated
- 2025-05-30
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01242215. Inclusion in this directory is not an endorsement.